Features – BioTuesdays

This Week's Feature

9 Meters Biopharma targeting rare and unmet needs in GI disorders

9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and celiac disease, an...

October 27, 2020

Features

Novamind building infrastructure for regulated psychedelic industry

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

October 20, 2020

Features

Lantern Pharma applying AI to discover and develop cancer therapeutics

Lantern Pharma (NASDAQ:LTRN) is using its RADR AI platform to identify abandoned drug candidates and develop new drugs that may prove effective in treating certain cancers.

October 13, 2020

Features

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Features

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

September 22, 2020

Features

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Features

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary uro-oncology...

September 8, 2020

Features

IDbyDNA commercializing Explify platform for comprehensive pathogen detection and surveillance

Closely-held clinical metagenomics company, IDbyDNA, is commercializing its Explify platform with the goal of replacing traditional pathogen detection with a data-driven approach. “Our vision is to deploy our...

September 1, 2020

Features

Axolotl Biosciences developing bioink for 3D neural tissue bioprinting

Closely-held Axolotl Biosciences is developing a bioink specifically formulated for the bioprinting of neural tissue, for biotechnology and pharmaceutical companies to use for research and development purposes. “Last...

August 25, 2020

Features

Chiasma readies U.S. launch of first oral somatostatin analog for acromegaly

On the heels of an FDA approval, Chiasma (NASDAQ:CHMA) is preparing for the U.S. launch of MYCAPSSA, the first orally administered somatostatin analog for the long-term maintenance treatment of acromegaly in patients...

August 18, 2020

Features

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...

August 11, 2020

Features

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

Fueled by decades of research in protein dysregulation and fundamental neuroscience, Prothena (NASDAQ:PRTA) is advancing a pipeline of therapeutic candidates with the potential to change the course of diseases such as...

August 4, 2020

Features

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

InspireMD (NYSE American:NSPR) is awaiting a decision from the FDA for an investigational device exemption as a steppingstone for a pivotal trial of its CE Mark-approved CGuard Carotid Stent System for the prevention of...

July 28, 2020

Features

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Wally Klemp, Executive Chairman Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80%...

July 21, 2020

Features

NeuroOne developing electrode technology to treat neurological conditions

Dave Rosa, President and CEO NeuroOne (OTCQB:NMTC) is developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of various neurological conditions, including epilepsy...

July 14, 2020

Features

Loki Therapeutics harnessing antigens from traditional childhood vaccinations for immunotherapy

Unlike the traditional approach to immunotherapy, which teaches the body to recognize tumor antigens as something foreign to be attacked, closely-held Loki Therapeutics’ AWAKE technology makes cancer appear as something...

July 7, 2020

Features

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Passage Bio (NASDAQ:PASG) is focused on developing transformative, differentiated therapies for rare, life-threatening monogenic CNS disorders, with the goal of mitigating development risk. “We believe that our rigorous...

June 30, 2020

Features

CohBar developing therapeutics from mitochondrial DNA

CohBar (NASDAQ:CWBR) is transforming peptides encoded and expressed by mitochondria, some of which control a wide range of systems in the body, into novel therapeutics. “Harnessing the power of mitochondria biology to...

June 23, 2020

Features

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

June 16, 2020

Features

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

Ian Koenig, SVP, Life Sciences at Investis Digital In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and...

June 9, 2020

Features

Chris Kaplan of ITG talks up market-making in capital markets

As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...

June 2, 2020

9 Meters Biopharma targeting rare and unmet needs in GI disorders

Novamind building infrastructure for regulated psychedelic industry

Lantern Pharma applying AI to discover and develop cancer therapeutics

Monopar Therapeutics readies two key clinical trials in fourth quarter

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

BioCardia developing autologous and allogenic cardiovascular cell therapies

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

IDbyDNA commercializing Explify platform for comprehensive pathogen detection and surveillance

Axolotl Biosciences developing bioink for 3D neural tissue bioprinting

Chiasma readies U.S. launch of first oral somatostatin analog for acromegaly

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

NeuroOne developing electrode technology to treat neurological conditions

Loki Therapeutics harnessing antigens from traditional childhood vaccinations for immunotherapy

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

CohBar developing therapeutics from mitochondrial DNA

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

Chris Kaplan of ITG talks up market-making in capital markets

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter